CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection FractionMichael McDonald, Amelia Yip, Sean Virani et al.|Canadian Journal of Cardiology|2021Cited by 290
Global Variations in Heart Failure Etiology, Management, and OutcomesYing Tung Sia, César Minelli, António Sousa et al.|JAMA|2023Cited by 164
CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in AmyloidosisEileen O’Meara, Bruce Sussex, Michael McDonald et al.|Canadian Journal of Cardiology|2020Cited by 121
Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac AmyloidosisNowell M. Fine, Shelley Zieroth, Margot K. Davis et al.|Canadian Journal of Cardiology|2020Cited by 112
Barriers to Goals of Care Discussions With Patients Who Have Advanced Heart Failure: Results of a Multicenter Survey of Hospital-Based Cardiology CliniciansJohn J. You, Heather J. Ross, Natasha Aleksova et al.|Journal of Cardiac Failure|2017Cited by 51